Maat Pharma SA
MaaT Pharma SA, a late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival. Its products pipeline includes MaaT013, that is in pivotal phase 3 clinical trial for the treatment of acute graft versus host diseases with gastrointestinal involvement; MaaT033, which is in phase 2b clinical trial for the improve… Read more
Maat Pharma SA (MAAT) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -1.853x
Based on the latest financial reports, Maat Pharma SA (MAAT) has a cash flow conversion efficiency ratio of -1.853x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-15.37 Million) by net assets (€8.29 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Maat Pharma SA - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Maat Pharma SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Maat Pharma SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Maat Pharma SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Menif Financial Services Ltd
TA:MNIF
|
-0.003x |
|
Lilama 18 JSC
VN:LM8
|
N/A |
|
ICH Co Ltd
KQ:368600
|
-0.014x |
|
Bhuwanatala Indah Permai Tbk
JK:BIPP
|
-0.007x |
|
Minim Inc
NASDAQ:MINM
|
0.736x |
|
TAIZHOU WATER GRP. H YC 1
F:GX5
|
N/A |
|
EFFNETPLATTFORMEN EV1 B
F:Y2Y
|
N/A |
|
Destinasi Tirta Nusantara Tbk
JK:PDES
|
0.250x |
Annual Cash Flow Conversion Efficiency for Maat Pharma SA (2017–2024)
The table below shows the annual cash flow conversion efficiency of Maat Pharma SA from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €10.34 Million | €-22.04 Million | -2.132x | -133.76% |
| 2023-12-31 | €20.47 Million | €-18.67 Million | -0.912x | -94.04% |
| 2022-12-31 | €26.81 Million | €-12.61 Million | -0.470x | -136.32% |
| 2021-12-31 | €39.86 Million | €-7.93 Million | -0.199x | +45.47% |
| 2020-12-31 | €15.94 Million | €-5.81 Million | -0.365x | -133.18% |
| 2019-12-31 | €-4.57 Million | €-5.02 Million | 1.099x | +136.04% |
| 2018-12-31 | €1.27 Million | €-3.87 Million | -3.050x | -315.12% |
| 2017-12-31 | €5.27 Million | €-3.87 Million | -0.735x | -- |